Fosamax and Osteonecrosis of the Jaw: Understanding the Risk and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, discussions of pharmaceutical safety have historically emphasized population-level data and clinical guidelines, often focusing on common adverse effects and standard risk communication. This heritage provides a structured approach to evaluating how medications interact with biological systems over time, yet it typically remains anchored in patient-oriented frameworks rather than occupational or environmental exposures. Transitioning from this general health perspective, a more targeted inquiry emerges when considering specific pharmaceutical agents and their potential to cause localized tissue damage under particular conditions of use. The case of bisphosphonate therapy, widely prescribed for bone density management, illustrates this pivot. While general health discourse addresses patient compliance and fracture prevention, a focused examination of exposure risk becomes necessary when evaluating rare but serious outcomes such as osteonecrosis of the jaw. This condition, though infrequent in the general patient population, raises distinct questions about cumulative drug exposure and individual susceptibility. The bridge from broad health education to occupational concern requires acknowledging that certain professional contexts may involve higher or more sustained exposure to pharmaceutical compounds. For instance, healthcare workers handling crushed tablets or administering intravenous formulations may face different risk profiles than typical patients. This shift in focus—from therapeutic benefit to exposure hazard—demands a reassessment of how risk is quantified and communicated across diverse populations, including those whose contact with the drug is not primarily for treatment but arises from occupational duties.

Fosamax and Osteonecrosis of the Jaw: Mechanisms and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition can lead to significant morbidity, including difficulty eating, speaking, and maintaining oral hygiene. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding suggests that bisphosphonates suppress bone turnover by inhibiting osteoclast activity. This suppression can impair the jawbone's ability to remodel and repair microdamage, particularly in areas subjected to mechanical stress or dental procedures. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that the jawbone's unique structure and high remodeling rate may make it particularly vulnerable to the effects of bisphosphonate therapy. The risk of ONJ in patients taking Fosamax is influenced by several factors. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Harm and Causation Evidence

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, observational data from a cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 regarding osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The timeline of symptom onset can be as short as one day or as long as several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of use, with a threefold increase after 2-3 years and an eightfold increase after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, the absolute risk remains low, and the condition is rare in the general population of osteoporosis patients. Patients who develop ONJ should discontinue Fosamax if severe symptoms develop, and most experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence indicates that Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of therapy and in the presence of other risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, and patients should be counseled on maintaining good oral hygiene and avoiding invasive dental procedures during treatment. The absolute risk remains low, but the condition can be serious and requires prompt management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of developing osteonecrosis of the jaw from Fosamax?

The absolute risk of ONJ in patients taking Fosamax is low, approximately 0.05% after 5 years of use. However, the risk increases with longer duration of therapy: a cohort study found a threefold increase after 2-3 years and an eightfold increase after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Risk is also higher in patients undergoing invasive dental procedures or with other risk factors such as cancer, chemotherapy, or poor oral hygiene.

How long does it take for Fosamax to cause osteonecrosis of the jaw?

Symptoms of ONJ can appear as early as one day after starting Fosamax or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with cumulative exposure, with higher risk after 2-3 years of treatment.

What should I do if I develop jaw pain while taking Fosamax?

If you develop jaw pain, swelling, or exposed bone, consult your healthcare provider immediately. They may recommend discontinuing Fosamax, especially if symptoms are severe. Most patients experience relief after stopping the medication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Avoid invasive dental procedures until evaluated.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.